tradingkey.logo

Illumina Q4 preliminary revenue rises 5%, beats analyst expectations

ReutersJan 13, 2026 2:12 PM


Overview

  • Genomics leader's preliminary Q4 revenue rises 5%, beating analyst expectations

  • Preliminary non-GAAP diluted EPS for Q4 ranges from $1.27 to $1.30

  • Fiscal year 2025 preliminary revenue remains flat compared to 2024


Outlook

  • Company did not provide specific guidance for future quarters or fiscal year


Result Drivers

  • EX-CHINA GROWTH - Co estimates 7% revenue growth excluding China in Q4

  • FLAT ANNUAL REVENUE - Fiscal year 2025 revenue estimated to remain flat compared to 2024


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$1.16 bln

$1.10 bln (16 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Illumina Inc is $130.00, about 10.7% below its January 12 closing price of $145.55

  • The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nPn5NxZ72a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI